Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 334

Results For "LA"

8967 News Found

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
R&D | December 20, 2025

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements


Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Drug Approval | December 20, 2025

Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%

Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension


Fortis invests  Rs. 840 crore for 300+ beds in Bengaluru
Hospitals | December 20, 2025

Fortis invests Rs. 840 crore for 300+ beds in Bengaluru

Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore


ystral expands in India with new Bangalore facility, boosting team & local production
News | December 19, 2025

ystral expands in India with new Bangalore facility, boosting team & local production

The expansion includes a larger technical and service team and increased local procurement


Novo Nordisk files FDA application for once-weekly obesity drug CagriSema
News | December 19, 2025

Novo Nordisk files FDA application for once-weekly obesity drug CagriSema

If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection


Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
Clinical Trials | December 19, 2025

Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron

At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo


GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy
News | December 19, 2025

GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy

GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies


Thyrocare appoints Dr Ramesh Kinha as COO
People | December 19, 2025

Thyrocare appoints Dr Ramesh Kinha as COO

Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems


Gilead’s new HIV therapy shows promising Phase 3 results
Clinical Trials | December 19, 2025

Gilead’s new HIV therapy shows promising Phase 3 results

The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy


Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
Clinical Trials | December 19, 2025

Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival